Vizsgálati helyszín
IDOR - Regional Bahia
Salvador, 41253-190, BrazíliaMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 16 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis3 vizsgálat
- Állapot
- Fut, nem toboroz12 vizsgálat
- Toboroz4 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC15 vizsgálat
- Janssen Pharmaceutica N.V., Belgium1 vizsgálat
Futó vizsgálatok
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· 3. fázis· Janssen Pharmaceutica N.V., Belgium· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek